Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T20:27:58.414Z.
Calculation as of: 2026-10-06T20:27:58.414Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ec3a954fc6de976752a3aa038aa366988fa42dfdceb22d2b84db27fd23854c8e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$1.62B
EV/EBITDA Ratio
56.65x
TTM Avg
223.11x
3Y Avg
223.11x
5Y Avg
223.11x
Market Cap
$1.63B
EV/EBITDA Ratio
6.76x
TTM Avg
10.54x
3Y Avg
14.62x
5Y Avg
19.17x
Market Cap
$1.59B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.57B
EV/EBITDA Ratio
N/A
TTM Avg
37.36x
3Y Avg
37.36x
5Y Avg
37.36x
Market Cap
$1.54B
EV/EBITDA Ratio
N/A
TTM Avg
399.33x
3Y Avg
399.33x
5Y Avg
399.33x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Septerna Inc (SEPN) | $1.61B | N/A | N/A | N/A | N/A |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.61B | N/A | N/A | N/A | N/A |
| Omnicell, Inc. (OMCL)vs › | $1.61B | 10.75x | 16.19x | 22.90x | 28.26x |
| uniQure N.V. (QURE)vs › | $1.60B | N/A | 1.92x | 1.94x | 1.94x |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.62B | 56.65x | 223.11x | 223.11x | 223.11x |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.63B | 6.76x | 10.54x | 14.62x | 19.17x |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | N/A | N/A | N/A | N/A |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | N/A | 37.36x | 37.36x | 37.36x |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | N/A | 399.33x | 399.33x | 399.33x |
| Innoviva, Inc. (INVA)vs › | $1.54B | 4.90x | 69.99x | 32.98x | 22.10x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
